These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8500221)
1. A slow-release methotrexate formulation for intrathecal chemotherapy. Chatelut E; Kim T; Kim S Cancer Chemother Pharmacol; 1993; 32(3):179-82. PubMed ID: 8500221 [TBL] [Abstract][Full Text] [Related]
2. An extended-release formulation of methotrexate for subcutaneous administration. Bonetti A; Chatelut E; Kim S Cancer Chemother Pharmacol; 1994; 33(4):303-6. PubMed ID: 8281623 [TBL] [Abstract][Full Text] [Related]
3. Sustained-release methotrexate for intracavitary chemotherapy. Chatelut E; Suh P; Kim S J Pharm Sci; 1994 Mar; 83(3):429-32. PubMed ID: 8207696 [TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750 [TBL] [Abstract][Full Text] [Related]
5. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Kim S; Kim DJ; Geyer MA; Howell SB Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced? Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463 [TBL] [Abstract][Full Text] [Related]
7. Extended-release formulation of morphine for subcutaneous administration. Kim T; Kim J; Kim S Cancer Chemother Pharmacol; 1993; 33(3):187-90. PubMed ID: 8269598 [TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Bleyer WA; Dedrick RL Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895 [TBL] [Abstract][Full Text] [Related]
9. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Kim S; Khatibi S; Howell SB; McCully C; Balis FM; Poplack DG Cancer Res; 1993 Apr; 53(7):1596-8. PubMed ID: 8453629 [TBL] [Abstract][Full Text] [Related]
10. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Glantz MJ; Van Horn A; Fisher R; Chamberlain MC Cancer; 2010 Apr; 116(8):1947-52. PubMed ID: 20151421 [TBL] [Abstract][Full Text] [Related]
11. CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration. Ogushi N; Sasaki K; Shimoda M J Vet Med Sci; 2017 Feb; 79(2):320-327. PubMed ID: 27916761 [TBL] [Abstract][Full Text] [Related]
12. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. Ramu A; Fusner JE; Blaschke T; Glaubiger DL Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360 [TBL] [Abstract][Full Text] [Related]
13. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Angst MS; Drover DR Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293 [TBL] [Abstract][Full Text] [Related]
14. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Mason WP; Yeh SD; DeAngelis LM Neurology; 1998 Feb; 50(2):438-44. PubMed ID: 9484369 [TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. Phuphanich S; Maria B; Braeckman R; Chamberlain M J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075 [TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporin on distribution of methotrexate into the brain of rats. Ogushi N; Sasaki K; Shimoda M J Vet Med Sci; 2015 Sep; 77(9):1171-3. PubMed ID: 25947324 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine. Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611 [TBL] [Abstract][Full Text] [Related]
20. Intrathecal methotrexate-induced neurotoxicities. Nelson RW; Frank JT Am J Hosp Pharm; 1981 Jan; 38(1):65-8. PubMed ID: 7011005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]